Welcome to our dedicated page for Aldeyra Therapeutics news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeutics stock.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) is a biotechnology company dedicated to improving lives by developing products that treat aldehyde-mediated diseases. The company's mission is to discover and develop innovative therapies designed to tackle immune-mediated diseases. Aldeyra focuses primarily on inflammation, inborn errors of metabolism, and other diseases associated with toxic and pro-inflammatory aldehydes.
Key highlights of Aldeyra's portfolio include:
- ADX-102: In development for noninfectious anterior uveitis, allergic conjunctivitis, and dry eye disease.
- Reproxalap: A first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis.
- ADX-2191: A novel methotrexate formulation for proliferative vitreoretinopathy and retinitis pigmentosa.
Aldeyra's approach involves developing pharmaceuticals that modulate immunological systems, optimizing multiple pathways while minimizing toxicity. Recent achievements include positive top-line results from Phase 2 clinical trials and strategic partnerships, such as an exclusive option agreement with AbbVie.
The company is financially stable with sufficient resources projected to fund operations through late 2025, enabling continued advancement of its promising pipeline. Aldeyra’s innovative therapies hold the potential to address significant unmet medical needs in ophthalmology and systemic immune-mediated diseases.
Rhea-AI Summary
Aldeyra Therapeutics, Inc. (ALDX) receives a Complete Response Letter from the FDA for reproxalap, an investigational drug candidate for dry eye disease. The FDA states that the NDA did not demonstrate efficacy in treating ocular symptoms associated with dry eyes, requiring an additional trial. Aldeyra submitted a Special Protocol Assessment for a dry eye disease chamber crossover clinical trial, with top-line results anticipated in the first half of 2024. The potential NDA resubmission is also expected in the first half of 2024. Aldeyra plans to extend its cash runway into late 2025, with $143 million in cash, cash equivalents, and marketable securities as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
-
Rhea-AI Summary
Aldeyra Therapeutics has entered into an exclusive option agreement with AbbVie Inc. The agreement grants AbbVie the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in the U.S. and an exclusive license to do the same outside the U.S. Aldeyra will receive a $1 million non-refundable option fee and a $100 million upfront payment if AbbVie exercises the option. Aldeyra could also receive up to $300 million in regulatory and commercial milestone payments. The terms of the license agreement include profit and loss sharing between Aldeyra and AbbVie, with a 60% split for AbbVie and 40% for Aldeyra in the U.S. market. Aldeyra would also be eligible for tiered royalties on net sales of reproxalap outside the U.S. AbbVie will have the right of first negotiation for compounds owned or controlled by Aldeyra in the field of ophthalmology relating to treating conditions of the ocular surface.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
48.54%
Tags
-
Rhea-AI Summary
A lawsuit has been filed against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) by investors alleging violations of securities laws. The lawsuit claims that the company made false and misleading statements regarding the effectiveness of ADX-2191. Investors who purchased over $100,000 worth of ALDX shares between March 2022 and June 2023 should contact the Shareholders Foundation, Inc. Deadline for action is September 29, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
-
Rhea-AI Summary
Aldeyra Therapeutics announces positive results from Phase 2 clinical trial of ADX-2191 for retinitis pigmentosa
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
-
Rhea-AI Summary
Aldeyra Therapeutics to announce top-line results from Phase 2 clinical trial of ADX-629 in patients with chronic cough.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.26%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.44%
Tags
FAQ
What is the current stock price of Aldeyra Therapeutics (ALDX)?
The current stock price of Aldeyra Therapeutics (ALDX) is $5.45 as of January 3, 2025.
What is the market cap of Aldeyra Therapeutics (ALDX)?
The market cap of Aldeyra Therapeutics (ALDX) is approximately 318.6M.
What is Aldeyra Therapeutics' core business?
Aldeyra Therapeutics focuses on developing innovative therapies designed to treat immune-mediated diseases by modulating immunological systems.
What are some of Aldeyra's key product candidates?
Key product candidates include ADX-102, reproxalap, and ADX-2191, all targeting diseases like dry eye, allergic conjunctivitis, and retinitis pigmentosa.
What recent achievements has Aldeyra Therapeutics accomplished?
The company has reported positive Phase 2 clinical trial results and entered into a strategic partnership with AbbVie.
What is the financial outlook for Aldeyra Therapeutics?
Aldeyra is financially stable, with resources projected to fund operations through late 2025.
How does Aldeyra's approach to drug development differ?
Aldeyra develops pharmaceuticals that modulate immunological systems, optimizing multiple pathways at once while minimizing toxicity.
What is reproxalap?
Reproxalap is a first-in-class treatment for dry eye disease and allergic conjunctivitis, currently in late-stage development.
What diseases does ADX-2191 target?
ADX-2191 targets proliferative vitreoretinopathy and retinitis pigmentosa, both rare retinal diseases with no approved therapies.
What upcoming milestones does Aldeyra anticipate?
Aldeyra anticipates potential NDA submissions and further clinical trial results for its key product candidates in 2024.
What strategic partnerships has Aldeyra entered into?
Aldeyra has an exclusive option agreement with AbbVie for the development and commercialization of reproxalap.
How does Aldeyra Therapeutics impact the field of ophthalmology?
Aldeyra is developing therapies that may provide significant relief for conditions like dry eye disease and retinitis pigmentosa, addressing substantial unmet medical needs in ophthalmology.
Aldeyra Therapeutics, Inc.
Nasdaq:ALDX
ALDX Rankings
ALDX Stock Data
318.59M
48.82M
2.44%
62.19%
5.73%
Biotechnology
Pharmaceutical Preparations
United States of America
LEXINGTON